Positive News Sentiment NASDAQ:NRXP NRx Pharmaceuticals - NRXP Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding NRx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.23 -0.02 (-1.60%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.18▼$1.2650-Day Range$1.01▼$1.4852-Week Range$0.49▼$3.54Volume246,822 shsAverage Volume338,708 shsMarket Capitalization$83.26 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media NRx Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside143.9% Upside$3.00 Price TargetShort InterestHealthy3.30% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingBalancedInsiders Both Buying and SellingProj. Earnings GrowthGrowingFrom ($0.67) to ($0.62) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.50 out of 5 starsMedical Sector162nd out of 1,055 stocksPharmaceutical Preparations Industry73rd out of 519 stocks 3.5 Analyst's Opinion Consensus RatingNRx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, NRx Pharmaceuticals has a forecasted upside of 143.9% from its current price of $1.23.Amount of Analyst CoverageNRx Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.30% of the float of NRx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverNRx Pharmaceuticals has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NRx Pharmaceuticals has recently decreased by 7.09%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNRx Pharmaceuticals does not currently pay a dividend.Dividend GrowthNRx Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NRXP. Previous Next 3.3 News and Social Media Coverage News SentimentNRx Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for NRx Pharmaceuticals this week, compared to 1 article on an average week.Search Interest12 people have searched for NRXP on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NRx Pharmaceuticals insiders have sold just slightly more of their company's stock than they have bought. Specifically, they have bought $441,204.00 in company stock and sold $504,956.00 in company stock. It is common for insiders to sell company stock at intervals simply to diversify their holdings.Percentage Held by Insiders25.70% of the stock of NRx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 6.09% of the stock of NRx Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for NRx Pharmaceuticals are expected to grow in the coming year, from ($0.67) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NRx Pharmaceuticals is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NRx Pharmaceuticals is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNRx Pharmaceuticals has a P/B Ratio of 3.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About NRx Pharmaceuticals (NASDAQ:NRXP) StockNRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.Read More Receive NRXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address NRXP Stock News HeadlinesJanuary 19, 2023 | finance.yahoo.comNRx Pharmaceuticals Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101January 5, 2023 | finance.yahoo.comNRx Pharmaceuticals to Present Scientific Update at the 6th Annual Sachs Associates Neuroscience Innovation Forum in Conjunction with the 2023 J.P. Morgan Healthcare ConferenceJanuary 27, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 3, 2023 | finance.yahoo.comNRx Pharmaceuticals Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality - First Clinical Site ContractedDecember 5, 2022 | finance.yahoo.comNRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical AffairsDecember 2, 2022 | finance.yahoo.comNRx Receives Nasdaq Notice of Listing ComplianceNovember 24, 2022 | au.finance.yahoo.comThe Independent Director of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), Chaim Hurvitz, Just Bought 30% More SharesNovember 14, 2022 | bizjournals.comNRx agrees to relinquish rights to experimental Covid-19 therapy in settlement with Relief TherapeuticsJanuary 27, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…November 14, 2022 | finance.yahoo.comNRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business UpdateNovember 14, 2022 | markets.businessinsider.comNRx Pharma To Transfer Aviptadil Development Program Assets To Relief TherapeuticsNovember 12, 2022 | msn.comEarnings Outlook For NRX PharmaceuticalsNovember 9, 2022 | seekingalpha.comNRx Pharma announces commercial production of drug targeted at suicidal depressionNovember 9, 2022 | finance.yahoo.comNRx Pharmaceuticals Produces First Phase 3-stage NRX-101 Drug Made Using Commercial ProcessNovember 7, 2022 | finance.yahoo.comNRx Pharmaceuticals Closes $11 Million Unsecured Debt FinancingSeptember 23, 2022 | finance.yahoo.comNRx Pharmaceuticals, Inc. (NRXP)September 7, 2022 | wsj.comNRX Pharmaceuticals Inc.August 22, 2022 | finance.yahoo.comNRx, Relief Therapeutics reach tentative agreement to resolve litigation tied to Covid-19 therapy candidateAugust 17, 2022 | investing.comNRx Pharmaceuticals, Inc. Reports Q2 Loss of $0.10August 16, 2022 | seekingalpha.comNRx Pharmaceuticals, Inc. (NRXP) CEO Stephen Willard on Q2 2022 Results - Earnings Call TranscriptAugust 16, 2022 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NRx Pharmaceuticals, Inc. - NRXP; NRXPWAugust 15, 2022 | finance.yahoo.comNRx Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Results Focusing on Reactivation & Advancement of its Psychiatry FranchiseAugust 10, 2022 | finance.yahoo.com/C O R R E C T I O N -- NRx Pharmaceuticals, Inc./August 3, 2022 | marketwatch.comThinking about buying stock in Ford Motor, Missfresh, Intel Corp, Ontrak, or NRX Pharmaceuticals?July 29, 2022 | benzinga.comThinking about buying stock in Athersys, Geovax Labs, NRX Pharmaceuticals, Marathon Digital, or Trade Desk?July 13, 2022 | bizjournals.comNRx Pharmaceuticals names new CEOJuly 13, 2022 | nasdaq.comNRx Pharmaceuticals Appoints Stephen Willard As CEOSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NRXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address NRXP Company Calendar Last Earnings11/14/2022Today1/27/2023Next Earnings (Estimated)3/30/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NRXP CUSIPN/A CIK1719406 Webwww.bigrockpartners.com Phone(484) 254-6134FaxN/AEmployees2Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.00 High Stock Price Forecast$4.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+143.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-93,060,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-275.44% Return on Assets-195.11% Debt Debt-to-Equity RatioN/A Current Ratio3.08 Quick Ratio3.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book3.51Miscellaneous Outstanding Shares67,691,000Free Float50,294,000Market Cap$83.26 million OptionableNot Optionable Beta0.97 Key ExecutivesStephen H. WillardChief Executive Officer & DirectorRobert BesthofChief Commercial Officer & Head-OperationsSeth L. van VoorheesChief Financial Officer & TreasurerCarrie M. CarrettaSenior VP-Clinical Development & Medical AffairsDennis K. McBrideChief Strategy OfficerKey CompetitorsLongeveronNASDAQ:LGVNImmunicNASDAQ:IMUXLAVA TherapeuticsNASDAQ:LVTXHomology MedicinesNASDAQ:FIXXSyros PharmaceuticalsNASDAQ:SYRSView All CompetitorsInsiders & InstitutionsExchange Traded Concepts LLCBought 16,322 shares on 1/18/2023Ownership: 0.040%Stephen H WillardBought 50,000 shares on 12/16/2022Total: $58,500.00 ($1.17/share)Voorhees Seth VanBought 30,000 shares on 12/16/2022Total: $33,000.00 ($1.10/share)Jonathan C JavittSold 400,000 sharesTotal: $400,000.00 ($1.00/share)Daniel C JavittSold 13,730 sharesTotal: $20,595.00 ($1.50/share)View All Insider TransactionsView All Institutional Transactions NRXP Stock - Frequently Asked Questions Should I buy or sell NRx Pharmaceuticals stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NRx Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NRXP shares. View NRXP analyst ratings or view top-rated stocks. What is NRx Pharmaceuticals' stock price forecast for 2023? 2 Wall Street analysts have issued 12-month target prices for NRx Pharmaceuticals' shares. Their NRXP share price forecasts range from $2.00 to $4.00. On average, they anticipate the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 140.0% from the stock's current price. View analysts price targets for NRXP or view top-rated stocks among Wall Street analysts. How have NRXP shares performed in 2023? NRx Pharmaceuticals' stock was trading at $1.11 on January 1st, 2023. Since then, NRXP shares have increased by 12.6% and is now trading at $1.25. View the best growth stocks for 2023 here. When is NRx Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023. View our NRXP earnings forecast. How were NRx Pharmaceuticals' earnings last quarter? NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) posted its quarterly earnings results on Monday, November, 14th. The company reported ($0.14) EPS for the quarter, hitting the consensus estimate of ($0.14). What is NRx Pharmaceuticals' stock symbol? NRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "NRXP." Who are NRx Pharmaceuticals' major shareholders? NRx Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Exchange Traded Concepts LLC (0.04%). Insiders that own company stock include Alessandra Daigneault, Chaim Hurvitz, Daniel C Javitt, Jonathan C Javitt, Patrick John Flynn, Robert Besthof, Stephen H Willard and Voorhees Seth Van. View institutional ownership trends. How do I buy shares of NRx Pharmaceuticals? Shares of NRXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is NRx Pharmaceuticals' stock price today? One share of NRXP stock can currently be purchased for approximately $1.25. How much money does NRx Pharmaceuticals make? NRx Pharmaceuticals (NASDAQ:NRXP) has a market capitalization of $84.61 million. The company earns $-93,060,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. How can I contact NRx Pharmaceuticals? NRx Pharmaceuticals' mailing address is 2645 N. Federal Highway Suite 230, Delray Beach FL, 33483. The official website for the company is www.bigrockpartners.com. The company can be reached via phone at (484) 254-6134 or via email at rsheffield@nrxpharma.com. This page (NASDAQ:NRXP) was last updated on 1/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.